

biopharmaceutical company with a
pipeline of selective oral immunology
therapies focused on treating chronic
inflammatory and autoimmune diseases.
Selective
Oral Drugs in
Immunology


small molecule products: lead development
program, vidofludimus calcium (IMU-838), is a
selective DHODH inhibitor; IMU-935 is a
selective inverse agonist of RORγt; and IMU-856
targets the restoration of the intestinal
barrier function.
Products in
Clinical
Development


orally available treatment options with sound
therapeutic efficacy and outstanding safety
and tolerability available to multiple sclerosis
patients, thereby improving the quality
of their lives.
Patients New, Safe
and Easy-to-Use
Treatment Options
in Tablet Form


and well-tolerated orally available
treatment options to patients suffering
from psoriasis in order to improve their
lives by eliminating the disturbing side
effects of the disease.
Convenient,
Oral Treatment
Options Available
to Patients
Press Releases & Events
Latest News.
Questions?
Get in touch.
Immunic, Inc. (Nasdaq: IMUX) Stock Quote: